NO20004491L - Blanding - Google Patents

Blanding

Info

Publication number
NO20004491L
NO20004491L NO20004491A NO20004491A NO20004491L NO 20004491 L NO20004491 L NO 20004491L NO 20004491 A NO20004491 A NO 20004491A NO 20004491 A NO20004491 A NO 20004491A NO 20004491 L NO20004491 L NO 20004491L
Authority
NO
Norway
Prior art keywords
disease
alzheimer
mixture
dementia
mammals
Prior art date
Application number
NO20004491A
Other languages
English (en)
Other versions
NO20004491D0 (no
Inventor
Robert Glinecke
William Muldoon
Joseph Sauer
Susan Marie Milosovich
Laurence Rosseau
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9805192.3A external-priority patent/GB9805192D0/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp filed Critical Smithkline Beecham Plc
Publication of NO20004491D0 publication Critical patent/NO20004491D0/no
Publication of NO20004491L publication Critical patent/NO20004491L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Confectionery (AREA)

Abstract

Doseformer med kontrollert frigjøring som er nyttige ved behandling og/eller forebygging av demens, omfattende Alzheimers sykdom, hos pattedyr og for å forbedre amyloid-forløperprotein-prosessering langs en ikke-amyloidogen bane hos pasienter som lider av eller med risiko for å utvikle, Alzheimers sykdom.
NO20004491A 1998-03-11 2000-09-08 Blanding NO20004491L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US7748098P 1998-03-11 1998-03-11
US7752798P 1998-03-11 1998-03-11
GBGB9805192.3A GB9805192D0 (en) 1998-03-11 1998-03-11 Composition
PCT/EP1999/001557 WO1999045924A1 (en) 1998-03-11 1999-03-05 Composition

Publications (2)

Publication Number Publication Date
NO20004491D0 NO20004491D0 (no) 2000-09-08
NO20004491L true NO20004491L (no) 2000-09-08

Family

ID=27269240

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004491A NO20004491L (no) 1998-03-11 2000-09-08 Blanding

Country Status (16)

Country Link
US (1) US6451343B1 (no)
EP (1) EP1061918A1 (no)
JP (1) JP2002506031A (no)
KR (1) KR20010034588A (no)
CN (1) CN1292696A (no)
AR (1) AR018147A1 (no)
AU (1) AU748396C (no)
CA (1) CA2323177A1 (no)
CO (1) CO5080740A1 (no)
HU (1) HUP0101043A3 (no)
IL (1) IL138192A0 (no)
NO (1) NO20004491L (no)
NZ (1) NZ505807A (no)
PL (1) PL342600A1 (no)
TR (1) TR200002626T2 (no)
WO (1) WO1999045924A1 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2813651B1 (fr) 2000-09-05 2004-06-11 Valeo Appareil d'accouplement hydrocinetique, notamment pour vehicule automobile
CA2470636A1 (en) * 2001-12-20 2003-07-03 Pharmacia Corporation Zero-order sustained released dosage forms and method of making the same
AR040683A1 (es) * 2002-07-25 2005-04-13 Pharmacia Corp Composicion de tabletas de liberacion sostenida que comprende un agonista de los receptores de la dopamina
PA8578501A1 (es) * 2002-07-25 2005-02-04 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
US20070196481A1 (en) * 2002-07-25 2007-08-23 Amidon Gregory E Sustained-release tablet composition
UA93608C2 (ru) 2004-08-13 2011-02-25 Берингер Ингельхайм Интернациональ Гмбх композициЯ таблетки пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, СПОСОБ EE ИЗГОТОВЛЕНИЯ И EE ПРИМЕНЕНИЕ
CN101022788B (zh) * 2004-08-13 2010-11-10 贝林格尔·英格海姆国际有限公司 包含普拉克索或其可药用盐的延长释放小球制剂、其制备方法及其用途
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
EP1988875A2 (en) * 2006-02-10 2008-11-12 Boehringer Ingelheim International GmbH Modified release formulation
US20080014257A1 (en) * 2006-07-14 2008-01-17 Par Pharmaceutical, Inc. Oral dosage forms
US9290759B2 (en) * 2010-08-25 2016-03-22 The Trustees Of Columbia University In The City Of New York Optimized miRNA constructs
PL3325444T3 (pl) 2015-07-20 2021-12-06 Acadia Pharmaceuticals Inc. Sposoby wytwarzania N-(4-fluorobenzylo)-N-(1-metylopiperydyn-4-ylo)-N'-(4-(2-metylopropyloksy)fenylometylo)karbamidu oraz jego soli winianowej i postaci polimorficznej C
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
EP3558311A1 (en) 2016-12-20 2019-10-30 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
WO2018200977A1 (en) 2017-04-28 2018-11-01 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
WO2019046167A1 (en) * 2017-08-30 2019-03-07 Acadia Pharmaceuticals Inc. PIMAVANSERIN FORMULATIONS
US11648242B2 (en) * 2019-12-12 2023-05-16 Aurobindo Pharma Ltd Pharmaceutical composition comprising pimavanserin, process of preparation and use thereof
WO2026018155A1 (en) 2024-07-16 2026-01-22 Syremis Therapeutics Ltd. Combinations of sabcomeline with long-acting non-cns penetrant muscarinic antagonists
WO2026018154A1 (en) 2024-07-16 2026-01-22 Syremis Therapeutics Ltd. Combinations of sabcomeline with non-cns penetrant muscarinic antagonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU207444B (en) 1990-07-12 1993-04-28 Biorex Kutato Fejlesztoe Kft Method for producing therapeutical preparation suitable for treating alzheimer-disease
US5433951A (en) * 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
GB9421472D0 (en) 1994-10-25 1994-12-07 Smithkline Beecham Plc Novel methods
AR004178A1 (es) 1995-07-29 1998-11-04 Smithkline Beecham Plc Procedimiento para la formulacion de un farmaco, una composicion farmaceutica obtenible mediante este procedimiento y el uso de la misma.
GB9619074D0 (en) 1996-09-12 1996-10-23 Smithkline Beecham Plc Composition

Also Published As

Publication number Publication date
AR018147A1 (es) 2001-10-31
AU748396B2 (en) 2002-06-06
NZ505807A (en) 2003-01-31
WO1999045924A1 (en) 1999-09-16
IL138192A0 (en) 2001-11-25
CA2323177A1 (en) 1999-09-16
AU3033299A (en) 1999-09-27
TR200002626T2 (tr) 2001-03-21
AU748396C (en) 2003-01-23
HUP0101043A3 (en) 2002-02-28
HUP0101043A2 (hu) 2001-12-28
NO20004491D0 (no) 2000-09-08
PL342600A1 (en) 2001-06-18
US6451343B1 (en) 2002-09-17
KR20010034588A (ko) 2001-04-25
EP1061918A1 (en) 2000-12-27
CO5080740A1 (es) 2001-09-25
CN1292696A (zh) 2001-04-25
JP2002506031A (ja) 2002-02-26

Similar Documents

Publication Publication Date Title
NO20004491L (no) Blanding
Peng et al. Increased proNGF levels in subjects with mild cognitive impairment and mild Alzheimer disease
NO20092874L (no) Forhindring og behandling av amyloidogen sykdom
Keck et al. Proteasome inhibition by paired helical filament‐tau in brains of patients with Alzheimer's disease
Popa-Wagner et al. β-Amyloid precursor protein and β-amyloid peptide immunoreactivity in the rat brain after middle cerebral artery occlusion: effect of age
TW264480B (no)
Ghiso et al. Alzheimer's soluble amyloid β is a normal component of human urine
IS2925B (is) Ákvörðun á batahorfum sjúklings sem undirgengst meðhöndlun við Alzheimer-sjúkdómi
WO2004032868A3 (en) Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
NO992368L (no) FremgangsmÕter og forbindelser til inhibering av <beta>-amyloidfrigivning og/eller dets syntese
WO2003015691A3 (en) RAPID IMPROVEMENT OF COGNITION IN CONDITIONS RELATED TO A$g(b)
NO20004803L (no) Smilagening og anzurogenin for behandling av Alzheimers sykdom
WO1995024650A3 (en) Methods of diagnosing and treating preeclampsia
DK1416965T3 (da) Assayfremgangsmåde til Alzheimers sygdom
NO20001869L (no) FremgangsmÕte for behandling av Alzheimers sykdom
EP1141251A4 (en) CONNECTIONS, SCREENING METHOD AND METHOD OF TREATING DISEASES OF THE CENTRAL AND PERIPHERAL NERVOUS SYSTEM
WO1999048489A3 (en) Melatonin for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
Luo et al. Homocysteine induces τ hyperphosphorylation in rats
Kim et al. C-terminal fragment of Alzheimer's amyloid precursor protein inhibits sodium/calcium exchanger activity in SK-N-SH cell
Cavani et al. Plasma levels of amyloid β 40 and 42 are independent from ApoE genotype and mental retardation in Down syndrome
NO993407L (no) Fremstilling av proteinpreparater med nedsatt aggregatinnhold
AU551361B2 (en) Pharmaceutical product and preparation method thereof
DE69531952D1 (de) Verwendung des erythropoietins zur behandlung von rheumatoider arthritis
DK0786998T3 (da) Anvendelse af [R-(Z)]-alfa-(metoxyimino)-alfa-(1-azabicyclo[2.2.2]oct-3-yl)acetonitril til reduktion af amyloid-beta-A4-dannelse ved Alzheimer's sygdom
BR9908374A (pt) Composição

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application